0001156039-24-000026.txt : 20240305
0001156039-24-000026.hdr.sgml : 20240305
20240305162108
ACCESSION NUMBER: 0001156039-24-000026
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BOUDREAUX GAIL
CENTRAL INDEX KEY: 0001287920
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16751
FILM NUMBER: 24720766
MAIL ADDRESS:
STREET 1: GENZYME CORP.
STREET 2: 500 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Elevance Health, Inc.
CENTRAL INDEX KEY: 0001156039
STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324]
ORGANIZATION NAME: 02 Finance
IRS NUMBER: 352145715
STATE OF INCORPORATION: IN
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 220 VIRGINIA AVENUE
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46204
BUSINESS PHONE: 8003311476
MAIL ADDRESS:
STREET 1: 220 VIRGINIA AVENUE
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46204
FORMER COMPANY:
FORMER CONFORMED NAME: Anthem, Inc.
DATE OF NAME CHANGE: 20141202
FORMER COMPANY:
FORMER CONFORMED NAME: WELLPOINT, INC
DATE OF NAME CHANGE: 20100105
FORMER COMPANY:
FORMER CONFORMED NAME: WELLPOINT INC
DATE OF NAME CHANGE: 20041130
4
1
wk-form4_1709673632.xml
FORM 4
X0508
4
2024-03-01
0
0001156039
Elevance Health, Inc.
ELV
0001287920
BOUDREAUX GAIL
220 VIRGINIA AVENUE
INDIANAPOLIS
IN
46204
1
1
0
0
President and CEO
0
Common Stock
2024-03-01
4
F
0
19256
499.11
D
117777
D
Common Stock
2024-03-01
4
A
0
8415
0
A
126192
D
Common Stock
2024-03-01
4
A
0
34517
0
A
160709
D
Common Stock
60
I
Shares Held in Spouse's Revocable Trust
Employee Stock Option (Right to Buy)
499.11
2024-03-01
4
A
0
32480
0
A
2034-03-01
Common Stock
32480
32480
D
PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.
Represents restricted share units. Restrictions lapse as follows: 2,805 shares each on 3/1/2025, 3/1/2026, and 3/1/2027.
Represents performance based restricted share units. Restrictions lapse on 3/1/2024.
Balance includes 392.27 shares acquired on 3/24/2023, 389.71 shares acquired on 6/23/2023 and 388.21 shares acquired on 9/23/2023 through a dividend reinvestment plan.
The option represents a right to purchase a total of 32,480 shares, and is exercisable in one installment of 10,826 shares and two installments of 10,827 shares each, beginning on 3/1/2025, which is the one-year anniversary of the option grant date.
/s/ Kathleen S. Kiefer, Attorney in fact
2024-03-05